These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34774018)

  • 1. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
    Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study.
    Facha W; Tadesse T; Wolka E; Astatkie A
    Front Public Health; 2024; 12():1385441. PubMed ID: 39015389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.
    Chapola JC; Lee F; Bula A; Rosenberg NE; Tseka J; Chagomerana M; Hosseinipour MC; Tang JH
    BMC Womens Health; 2023 Sep; 23(1):478. PubMed ID: 37689628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J
    HIV Med; 2024 Jul; 25(7):826-839. PubMed ID: 38520085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
    Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
    J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
    Facha W; Tadesse T; Wolka E; Astatkie A
    PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I; Katana E; Agnes Odongpiny EL; Nalugga EA; Castelnuovo B; Fowler MG; Musoke P
    AIDS Res Ther; 2024 Apr; 21(1):23. PubMed ID: 38637785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
    Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
    J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda.
    Wagner Z; Wang Z; Stecher C; Karamagi Y; Odiit M; Haberer JE; Linnemayr S
    J Int AIDS Soc; 2024 Aug; 27(8):e26350. PubMed ID: 39155425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda.
    Alhassan Y; Twimukye A; Malaba T; Myer L; Waitt C; Lamorde M; Colbers A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Womens Health; 2022 Jun; 22(1):246. PubMed ID: 35729541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.
    Zakumumpa H; Kitutu FE; Ndagije HB; Diana NK; Ssanyu JN; Kiguba R
    BMC Infect Dis; 2021 Dec; 21(1):1222. PubMed ID: 34876050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
    George JW; Mattingly JE; Roland NJ; Small CM; Lamberty BG; Fox HS; Stauch KL
    Front Immunol; 2021; 12():639378. PubMed ID: 34093527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.